Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)

Heidi D. Klepin, Ellen Ritchie, Brittny Major-Elechi, Jennifer Le-Rademacher, Drew Seisler, Libby Storrick, Ben L. Sanford, Guido Marcucci, Weiqiang Zhao, Susan A. Geyer, Karla V. Ballman, Bayard L. Powell, Maria R. Baer, Wendy Stock, Harvey Jay Cohen, Richard M. Stone, Richard A. Larson, Geoffrey L. Uy

Research output: Contribution to journalArticle

Abstract

Objective: To demonstrate feasibility of performing geriatric assessment (GA) in the National Clinical Trials Network (NCTN) and to explore the utility of GA to characterize treatment tolerance. Materials and methods: We conducted a multisite companion study (CALGB 361006) to CALGB 11001, a phase 2 trial of adults ≥60 years old with newly diagnosed FLT3- mutated AML, testing the efficacy of adding sorafenib to intensive chemotherapy. On 361006, a GA was administered prior to induction and prior to post-remission therapy. The GA is divided into items requiring administration by a health care professional (HCP) and patient self-administered questionnaires. Feasibility outcomes were recruitment rate, time to GA completion, difficulty with GA administration, percent of patients requiring assistance, and satisfaction. Change in GA measures pre- and post-induction were compared using Wilcoxon signed rank test and McNemar's tests. Results: The recruitment rate was 80% (N = 43, median age 68 years). Median completion time of the GA was 30 min; (10 and 21 min for HCP and patients, respectively). HCP reported no difficulty completing assessments (100%). Most patients completed questionnaires without assistance (77%), and were satisfied with the length (89%). Self-reported physical function, mental health, social activity and nutritional parameters worsened after induction. Conclusion: GA is feasible to administer in the setting of intensive induction for older adults with AML in the NCTN and provides evidence of the impact of induction therapy on physical and emotional health.

Original languageEnglish (US)
JournalJournal of Geriatric Oncology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Geriatric Assessment
Acute Myeloid Leukemia
Therapeutics
Delivery of Health Care
Clinical Trials
Nonparametric Statistics
Mental Health
Drug Therapy

Keywords

  • Acute myeloid leukemia
  • Age
  • Feasibility
  • Geriatric assessment
  • Hematologic malignancy
  • Hematology
  • Leukemia
  • Older

ASJC Scopus subject areas

  • Oncology
  • Geriatrics and Gerontology

Cite this

Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia : Report of CALGB 361006 (Alliance). / Klepin, Heidi D.; Ritchie, Ellen; Major-Elechi, Brittny; Le-Rademacher, Jennifer; Seisler, Drew; Storrick, Libby; Sanford, Ben L.; Marcucci, Guido; Zhao, Weiqiang; Geyer, Susan A.; Ballman, Karla V.; Powell, Bayard L.; Baer, Maria R.; Stock, Wendy; Cohen, Harvey Jay; Stone, Richard M.; Larson, Richard A.; Uy, Geoffrey L.

In: Journal of Geriatric Oncology, 01.01.2019.

Research output: Contribution to journalArticle

Klepin, HD, Ritchie, E, Major-Elechi, B, Le-Rademacher, J, Seisler, D, Storrick, L, Sanford, BL, Marcucci, G, Zhao, W, Geyer, SA, Ballman, KV, Powell, BL, Baer, MR, Stock, W, Cohen, HJ, Stone, RM, Larson, RA & Uy, GL 2019, 'Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)', Journal of Geriatric Oncology. https://doi.org/10.1016/j.jgo.2019.10.002
Klepin, Heidi D. ; Ritchie, Ellen ; Major-Elechi, Brittny ; Le-Rademacher, Jennifer ; Seisler, Drew ; Storrick, Libby ; Sanford, Ben L. ; Marcucci, Guido ; Zhao, Weiqiang ; Geyer, Susan A. ; Ballman, Karla V. ; Powell, Bayard L. ; Baer, Maria R. ; Stock, Wendy ; Cohen, Harvey Jay ; Stone, Richard M. ; Larson, Richard A. ; Uy, Geoffrey L. / Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia : Report of CALGB 361006 (Alliance). In: Journal of Geriatric Oncology. 2019.
@article{731cb2a58f4e4a039c55d5ac3d702f57,
title = "Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)",
abstract = "Objective: To demonstrate feasibility of performing geriatric assessment (GA) in the National Clinical Trials Network (NCTN) and to explore the utility of GA to characterize treatment tolerance. Materials and methods: We conducted a multisite companion study (CALGB 361006) to CALGB 11001, a phase 2 trial of adults ≥60 years old with newly diagnosed FLT3- mutated AML, testing the efficacy of adding sorafenib to intensive chemotherapy. On 361006, a GA was administered prior to induction and prior to post-remission therapy. The GA is divided into items requiring administration by a health care professional (HCP) and patient self-administered questionnaires. Feasibility outcomes were recruitment rate, time to GA completion, difficulty with GA administration, percent of patients requiring assistance, and satisfaction. Change in GA measures pre- and post-induction were compared using Wilcoxon signed rank test and McNemar's tests. Results: The recruitment rate was 80{\%} (N = 43, median age 68 years). Median completion time of the GA was 30 min; (10 and 21 min for HCP and patients, respectively). HCP reported no difficulty completing assessments (100{\%}). Most patients completed questionnaires without assistance (77{\%}), and were satisfied with the length (89{\%}). Self-reported physical function, mental health, social activity and nutritional parameters worsened after induction. Conclusion: GA is feasible to administer in the setting of intensive induction for older adults with AML in the NCTN and provides evidence of the impact of induction therapy on physical and emotional health.",
keywords = "Acute myeloid leukemia, Age, Feasibility, Geriatric assessment, Hematologic malignancy, Hematology, Leukemia, Older",
author = "Klepin, {Heidi D.} and Ellen Ritchie and Brittny Major-Elechi and Jennifer Le-Rademacher and Drew Seisler and Libby Storrick and Sanford, {Ben L.} and Guido Marcucci and Weiqiang Zhao and Geyer, {Susan A.} and Ballman, {Karla V.} and Powell, {Bayard L.} and Baer, {Maria R.} and Wendy Stock and Cohen, {Harvey Jay} and Stone, {Richard M.} and Larson, {Richard A.} and Uy, {Geoffrey L.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jgo.2019.10.002",
language = "English (US)",
journal = "Journal of Geriatric Oncology",
issn = "1879-4068",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia

T2 - Report of CALGB 361006 (Alliance)

AU - Klepin, Heidi D.

AU - Ritchie, Ellen

AU - Major-Elechi, Brittny

AU - Le-Rademacher, Jennifer

AU - Seisler, Drew

AU - Storrick, Libby

AU - Sanford, Ben L.

AU - Marcucci, Guido

AU - Zhao, Weiqiang

AU - Geyer, Susan A.

AU - Ballman, Karla V.

AU - Powell, Bayard L.

AU - Baer, Maria R.

AU - Stock, Wendy

AU - Cohen, Harvey Jay

AU - Stone, Richard M.

AU - Larson, Richard A.

AU - Uy, Geoffrey L.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: To demonstrate feasibility of performing geriatric assessment (GA) in the National Clinical Trials Network (NCTN) and to explore the utility of GA to characterize treatment tolerance. Materials and methods: We conducted a multisite companion study (CALGB 361006) to CALGB 11001, a phase 2 trial of adults ≥60 years old with newly diagnosed FLT3- mutated AML, testing the efficacy of adding sorafenib to intensive chemotherapy. On 361006, a GA was administered prior to induction and prior to post-remission therapy. The GA is divided into items requiring administration by a health care professional (HCP) and patient self-administered questionnaires. Feasibility outcomes were recruitment rate, time to GA completion, difficulty with GA administration, percent of patients requiring assistance, and satisfaction. Change in GA measures pre- and post-induction were compared using Wilcoxon signed rank test and McNemar's tests. Results: The recruitment rate was 80% (N = 43, median age 68 years). Median completion time of the GA was 30 min; (10 and 21 min for HCP and patients, respectively). HCP reported no difficulty completing assessments (100%). Most patients completed questionnaires without assistance (77%), and were satisfied with the length (89%). Self-reported physical function, mental health, social activity and nutritional parameters worsened after induction. Conclusion: GA is feasible to administer in the setting of intensive induction for older adults with AML in the NCTN and provides evidence of the impact of induction therapy on physical and emotional health.

AB - Objective: To demonstrate feasibility of performing geriatric assessment (GA) in the National Clinical Trials Network (NCTN) and to explore the utility of GA to characterize treatment tolerance. Materials and methods: We conducted a multisite companion study (CALGB 361006) to CALGB 11001, a phase 2 trial of adults ≥60 years old with newly diagnosed FLT3- mutated AML, testing the efficacy of adding sorafenib to intensive chemotherapy. On 361006, a GA was administered prior to induction and prior to post-remission therapy. The GA is divided into items requiring administration by a health care professional (HCP) and patient self-administered questionnaires. Feasibility outcomes were recruitment rate, time to GA completion, difficulty with GA administration, percent of patients requiring assistance, and satisfaction. Change in GA measures pre- and post-induction were compared using Wilcoxon signed rank test and McNemar's tests. Results: The recruitment rate was 80% (N = 43, median age 68 years). Median completion time of the GA was 30 min; (10 and 21 min for HCP and patients, respectively). HCP reported no difficulty completing assessments (100%). Most patients completed questionnaires without assistance (77%), and were satisfied with the length (89%). Self-reported physical function, mental health, social activity and nutritional parameters worsened after induction. Conclusion: GA is feasible to administer in the setting of intensive induction for older adults with AML in the NCTN and provides evidence of the impact of induction therapy on physical and emotional health.

KW - Acute myeloid leukemia

KW - Age

KW - Feasibility

KW - Geriatric assessment

KW - Hematologic malignancy

KW - Hematology

KW - Leukemia

KW - Older

UR - http://www.scopus.com/inward/record.url?scp=85074509687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074509687&partnerID=8YFLogxK

U2 - 10.1016/j.jgo.2019.10.002

DO - 10.1016/j.jgo.2019.10.002

M3 - Article

C2 - 31668825

AN - SCOPUS:85074509687

JO - Journal of Geriatric Oncology

JF - Journal of Geriatric Oncology

SN - 1879-4068

ER -